Table 2 Clinical characteristics of HIV patients on second-line antiretroviral therapy in Eastern Amhara region, Northeast Ethiopia, December 2020–February 2021 (n = 714)
Clinical characteristics | Total (714) N (%) | Medication adherence (496) N (%) |
|---|---|---|
BMI | ||
 ≥ 18.5 kg/m2 | 545 (76.3) | 395 (72.5) |
 < 18.5 kg/m2 | 169 (23.7) | 101 (59.8) |
Functional status | ||
 Workable | 608 (85.2) | 435 (71.5) |
 Not workable | 106 (14.8) | 61 (57.5) |
WHO clinical stages | ||
 I and II | 685(95.9) | 478(69.8) |
 III and IV | 29 (4.1) | 18 (62.1) |
Last HIV viral load status | ||
 High viral load (VL ≥ 1000copies/mL) | 174 (24.4) | 91 (52.3) |
 Low viral load (VL < 1000 copies/mL) | 540 (75.6) | 405 (75.0) |
Last CD4 cells measurement | ||
 ≤ 450 cell/mm3 | 603 (84.5) | 412 (68.3) |
 > 450 cell/mm3 | 111 (15.5) | 84 (75.7) |
Drug substitution history | ||
 No | 505 (70.7) | 361 (71.5) |
 Yes | 209 (29.3) | 135 (64.6) |
Reported side effect | ||
 No | 640 (89.6) | 451 (70.5) |
 Yes | 74 (10.4) | 45 (60.8) |
Comorbidities status | ||
 No | 651 (91.2) | 457 (70.2) |
 Yes | 63 (8.8) | 39 (61.9) |
Second-line ART | ||
 TDF—3TC—ATV/r | 361 (50.6) | 259 (71.7) |
 AZT—3TC—ATV/r | 338 (47.3) | 230 (68.0) |
 TDF—3TC—LPV/r | 11 (1.5) | 4 (36.4) |
 AZT—3TC—LPV/r | 4 (0.6) | 3 (75) |